Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. 1995

S Klahr, and J A Breyer, and G J Beck, and V W Dennis, and J A Hartman, and D Roth, and T I Steinman, and S R Wang, and M E Yamamoto
National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.

In the Modification of Diet in Renal Disease Study, a follow-up (mean, 2.2 yr) of 200 study participants with autosomal dominant polycystic kidney disease (ADPKD) was conducted to determine the effect of lowering protein intake and blood pressure on the rate of decline in GFR. The rate of decline was faster in participants with ADPKD than in persons with other diagnoses, reflecting, in part, faster disease progression in the ADPKD group. Baseline characteristics that predicted a faster rate of decline in GFR in persons with ADPKD were greater serum creatinine (independent of GFR), greater urinary protein excretion, higher mean arterial pressure (MAP), and younger age. In patients with initial GFR values between 25 and 55 mL/min per 1.73 m2, neither assignment to a low-protein diet group nor assignment to a low blood pressure group significantly reduced the rate of decline of GFR in ADPKD participants. Similarly, the decline in GFR was not related to achieved protein intake or MAP. In participants with GFR values between 13 and 24 mL/min per 1.73 m2, assignment to the low MAP group led to a somewhat more rapid decline in GFR. However, the more rapid decline in GFR did not appear to be due to a detrimental effect of low blood pressure or the antihypertensive agents used to reach the low blood pressure goal. Lower protein intake, but not prescription of the keto acid-amino acid supplement, was marginally associated with a slower progression of renal disease.

UI MeSH Term Description Entries
D006977 Hypertension, Renal Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN. Hypertensions, Renal,Renal Hypertension,Renal Hypertensions
D007677 Kidney Function Tests Laboratory tests used to evaluate how well the kidneys are working through examination of blood and urine. Function Test, Kidney,Function Tests, Kidney,Kidney Function Test,Test, Kidney Function,Tests, Kidney Function
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010349 Patient Compliance Voluntary cooperation of the patient in following a prescribed regimen. Client Adherence,Client Compliance,Non-Adherent Patient,Patient Adherence,Patient Cooperation,Patient Noncompliance,Patient Non-Adherence,Patient Non-Compliance,Patient Nonadherence,Therapeutic Compliance,Treatment Compliance,Adherence, Client,Adherence, Patient,Client Compliances,Compliance, Client,Compliance, Patient,Compliance, Therapeutic,Compliance, Treatment,Cooperation, Patient,Non Adherent Patient,Non-Adherence, Patient,Non-Adherent Patients,Non-Compliance, Patient,Nonadherence, Patient,Noncompliance, Patient,Patient Non Adherence,Patient Non Compliance,Patient, Non-Adherent,Therapeutic Compliances,Treatment Compliances
D010758 Phosphorus A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions. Black Phosphorus,Phosphorus-31,Red Phosphorus,White Phosphorus,Yellow Phosphorus,Phosphorus 31,Phosphorus, Black,Phosphorus, Red,Phosphorus, White,Phosphorus, Yellow
D011507 Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES. Proteinurias
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine

Related Publications

S Klahr, and J A Breyer, and G J Beck, and V W Dennis, and J A Hartman, and D Roth, and T I Steinman, and S R Wang, and M E Yamamoto
March 1994, The New England journal of medicine,
S Klahr, and J A Breyer, and G J Beck, and V W Dennis, and J A Hartman, and D Roth, and T I Steinman, and S R Wang, and M E Yamamoto
November 1995, Annals of internal medicine,
S Klahr, and J A Breyer, and G J Beck, and V W Dennis, and J A Hartman, and D Roth, and T I Steinman, and S R Wang, and M E Yamamoto
May 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation,
S Klahr, and J A Breyer, and G J Beck, and V W Dennis, and J A Hartman, and D Roth, and T I Steinman, and S R Wang, and M E Yamamoto
December 1996, Journal of the American Society of Nephrology : JASN,
S Klahr, and J A Breyer, and G J Beck, and V W Dennis, and J A Hartman, and D Roth, and T I Steinman, and S R Wang, and M E Yamamoto
November 1999, Journal of the American Society of Nephrology : JASN,
S Klahr, and J A Breyer, and G J Beck, and V W Dennis, and J A Hartman, and D Roth, and T I Steinman, and S R Wang, and M E Yamamoto
December 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation,
S Klahr, and J A Breyer, and G J Beck, and V W Dennis, and J A Hartman, and D Roth, and T I Steinman, and S R Wang, and M E Yamamoto
August 1994, The New England journal of medicine,
S Klahr, and J A Breyer, and G J Beck, and V W Dennis, and J A Hartman, and D Roth, and T I Steinman, and S R Wang, and M E Yamamoto
August 1994, The New England journal of medicine,
S Klahr, and J A Breyer, and G J Beck, and V W Dennis, and J A Hartman, and D Roth, and T I Steinman, and S R Wang, and M E Yamamoto
August 1994, The New England journal of medicine,
S Klahr, and J A Breyer, and G J Beck, and V W Dennis, and J A Hartman, and D Roth, and T I Steinman, and S R Wang, and M E Yamamoto
September 1997, Hypertension (Dallas, Tex. : 1979),
Copied contents to your clipboard!